Raaj Medisafe

Why is Raaj Medisafe India Ltd falling/rising?

As of 07-Aug, Raaj Medisafe India Ltd's stock price is currently Rs 67.20, reflecting a 4.95% decline. The stock has shown a consistent downward trend, with significant drops over various periods and declining investor participation.

As of 07-Aug, Raaj Medisafe India Ltd's stock price is falling, currently at Rs 67.20, which reflects a decrease of Rs 3.5 or 4.95%. This decline is evident in the stock's performance over various periods, showing a 7.00% drop over the past week and a 7.31% decrease over the past month. Year-to-date, the stock has fallen by 4.01%, and over the past year, it has experienced a significant decline of 26.15%. <BR><BR>Today's trading activity indicates that the stock opened with a loss of 4.95% and has not traded above this opening price, indicating a lack of upward momentum. Additionally, the stock is currently trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, suggesting a bearish trend. The stock is also close to its 52-week low, being only 4.64% away from Rs 64.08. <BR><BR>Investor participation appears to be declining, as evidenced by a 31.82% drop in delivery volume compared to the 5-day average. Furthermore, the stock has shown erratic trading patterns, having not traded on 4 out of the last 20 days. These factors collectively contribute to the downward pressure on Raaj Medisafe India Ltd's stock price.

Which are the latest news on Raaj Medisafe?

When is the next results date for Raaj Medisafe India Ltd?

The next results date for Raaj Medisafe India Ltd is 12 August 2026.

The next results date for Raaj Medisafe India Ltd is scheduled for 12 August 2026.

Should I buy, sell or hold Raaj Medisafe India Ltd?

How big is Raaj Medisafe?

As of 10th June, Raaj Medisafe India Ltd has a market capitalization of 123.00 Cr, classifying it as a Micro Cap company, with recent Net Sales of 1.05 Cr and a Net Profit loss of 0.00 Cr. Shareholder's Funds are valued at 26.92 Cr, and Total Assets amount to 68.06 Cr.

As of 10th June, Raaj Medisafe India Ltd has a market capitalization of 123.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest two quarters, Raaj Medisafe reported Net Sales of 1.05 Cr. The Net Profit for the same period was a loss of 0.00 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025. Shareholder's Funds are valued at 26.92 Cr, while Total Assets amount to 68.06 Cr.

Who are in the management team of Raaj Medisafe?

The management team of Raaj Medisafe includes Arpit Bangur (Chairman), Navin Jhawar (Managing Director), and independent directors Rajesh Kumar Gupta, Vijendra Kumar Sood, and Krishna Jajoo, along with Sachin Sarda as Company Secretary & Compliance Officer.

The management team of Raaj Medisafe includes the following individuals:<BR><BR>1. **Arpit Bangur** - Chairman (Non-Executive)<BR>2. **Rajesh Kumar Gupta** - Independent Director<BR>3. **Vijendra Kumar Sood** - Independent Director<BR>4. **Krishna Jajoo** - Independent Director<BR>5. **Sachin Sarda** - Company Secretary & Compliance Officer<BR>6. **Navin Jhawar** - Managing Director<BR><BR>If you need more details about their roles or responsibilities, feel free to ask!

Who are the peers of the Raaj Medisafe?

Raaj Medisafe's peers include Emmbi Industries, Kaira Can, Hind.Tin Works, Clara Industries, Guj. Containers, AMD Industries, Barflex Polyfilm, and Mega Flex Plast. Its 1-year return is -7.88%, better than Emmbi Industries but worse than most peers, with growth rated as Excellent and capital structure as Below Average.

Peers: The peers of Raaj Medisafe are Emmbi Industries, Kaira Can, Hind.Tin Works, Clara Industries, Guj. Containers, AMD Industries, Barflex Polyfilm, and Mega Flex Plast.<BR><BR>Quality Snapshot: Excellent management risk is observed at Guj. Containers, while Average management risk is found at Emmbi Industries, Kaira Can, Hind.Tin Works, Clara Industries, Barflex Polyfilm, and Mega Flex Plast, and the rest. Growth is Excellent at Raaj Medisafe and Clara Industries, while Below Average growth is noted at Emmbi Industries, Kaira Can, Hind.Tin Works, AMD Industries, and the rest. Capital Structure is Excellent at Kaira Can and Barflex Polyfilm, Good at Guj. Containers and Mega Flex Plast, while Below Average is seen at Raaj Medisafe, Emmbi Industries, and AMD Industries.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Apt Packaging at 91.42%, while the lowest is Emmbi Industries at -27.43%. Raaj Medisafe's 1-year return is -7.88%, which is better than Emmbi Industries but worse than most of its peers. Additionally, the six-month return is negative for Emmbi Industries, Hind.Tin Works, AMD Industries, and Clara Industries.

What does Raaj Medisafe do?

Raaj Medisafe India Ltd manufactures medical disposable devices and operates in the micro-cap packaging industry. As of March 2026, it reported net sales of 25 Cr and a net loss of 3 Cr, with a market cap of INR 123 Cr.

Overview:<BR>Raaj Medisafe India Ltd is engaged in the manufacturing of medical disposable devices and operates within the micro-cap segment of the packaging industry.<BR><BR>History:<BR>The company was incorporated in September 1985 and was originally known as Manoj Surgical Industries Limited until it changed its name to Raaj Medisafe India Limited in July 2008. The latest quarterly results reported net sales and net profit for the period ending March 2026.<BR><BR>Financial Snapshot:<BR>- Net Sales: 25 Cr (Quarterly Results - Mar 2026)<BR>- Net Profit: -3 Cr (Quarterly Results - Mar 2026)<BR>- Market Cap: INR 123 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: 65.00<BR>- Industry P/E: 92<BR>- Dividend Yield: 0.00%<BR>- Debt-Equity: 1.10<BR>- Return on Equity: 3.96%<BR>- Price to Book: 2.64<BR><BR>Contact Details:<BR>Address: 106 Sector III, Industrial Area Pithampur Dhar Madhya Pradesh : 454774<BR>Tel: 91-7292-403192<BR>Email: info@medisafeindia.com<BR>Website: http://www.raajmedisafeindia.com

Are Raaj Medisafe India Ltd latest results good or bad?

Raaj Medisafe India Ltd's latest results for FY25 are strong, with a 44.2% revenue increase to ₹62.00 crores and a net profit doubling to ₹6.00 crores. However, concerns about a slight decrease in operating margin and a high debt-to-equity ratio suggest potential risks for investors.

Raaj Medisafe India Ltd's latest results for FY25 indicate a strong performance overall, showcasing significant growth and profitability. The company reported an annual revenue of ₹62.00 crores, which is a remarkable increase of 44.2% year-on-year. Additionally, net profit doubled to ₹6.00 crores, reflecting a 100% increase compared to the previous fiscal year. This growth is complemented by an impressive average return on equity (ROE) of 82.82%, highlighting the company's efficiency in generating returns for shareholders.<BR><BR>Despite these positive indicators, there are some concerns to consider. The operating margin has slightly decreased to 12.9% from 14.0% in FY24, indicating some pressure on operational efficiency as the company scales. Moreover, the company operates with a high debt-to-equity ratio of 1.77, which raises questions about its leverage and ability to manage debt, especially as interest costs have also increased.<BR><BR>In summary, while Raaj Medisafe India Ltd has demonstrated exceptional growth and profitability, the high leverage and slight margin pressure warrant careful monitoring. Overall, the results can be viewed as good, but potential investors should be aware of the associated risks.

How has been the historical performance of Raaj Medisafe?

Raaj Medisafe has shown significant growth from March 2019 to March 2025, with net sales increasing from 4.80 Cr to 62.42 Cr and a turnaround from losses to profits in operating profit, profit before tax, and profit after tax. Total assets rose from 13.59 Cr to 68.06 Cr, indicating strong financial recovery and growth.

Answer:<BR>The historical performance of Raaj Medisafe shows significant growth in net sales and profitability over the years, culminating in the fiscal year ending March 2025.<BR><BR>Breakdown:<BR>Raaj Medisafe's net sales have increased from 4.80 Cr in March 2019 to 62.42 Cr in March 2025, reflecting a robust growth trajectory. Total operating income followed a similar trend, rising from 4.80 Cr in March 2019 to 62.42 Cr in March 2025. The company's operating profit (PBDIT) has also improved, moving from a loss of 0.78 Cr in March 2019 to a profit of 8.83 Cr in March 2025. Profit before tax has shown a positive trend, increasing from a loss of 1.59 Cr in March 2019 to a profit of 5.25 Cr in March 2025, while profit after tax reached 6.13 Cr in March 2025, up from a loss of 1.36 Cr in March 2020. The company's total assets have expanded significantly from 13.59 Cr in March 2020 to 68.06 Cr in March 2025, with total liabilities also increasing from 13.59 Cr to 34.51 Cr during the same period. Cash flow from operating activities remained stable, while cash flow from investing activities showed a negative trend, indicating ongoing investments in growth. Overall, Raaj Medisafe has demonstrated a strong recovery and growth in its financial performance over the years.

Who are the top shareholders of the Raaj Medisafe?

The top shareholders of Raaj Medisafe include Sushen Remedies Private Limited with 19.14%, individual investors with 23.05%, and Ramesh Chand Maheshvari as the highest public shareholder at 2.42%. There are no mutual funds or foreign institutional investors currently holding shares in the company.

The top shareholders of Raaj Medisafe include the promoters, with Sushen Remedies Private Limited holding the largest stake at 19.14%. Additionally, individual investors collectively own 23.05% of the company. The highest public shareholder is Ramesh Chand Maheshvari, who holds 2.42%. There are currently no mutual funds or foreign institutional investors (FIIs) holding shares in the company.

Is Raaj Medisafe overvalued or undervalued?

As of May 27, 2025, Raaj Medisafe's valuation has improved to very attractive, with strong growth potential indicated by a PE ratio of 17.03, an EV to EBITDA of 15.33, and a PEG ratio of 0.33, making it undervalued compared to peers like Poly Medicure and Blue Jet Health, despite recent underperformance against the Sensex.

As of 27 May 2025, the valuation grade for Raaj Medisafe has moved from attractive to very attractive, indicating a positive shift in its investment appeal. The company is currently undervalued, with a PE ratio of 17.03, an EV to EBITDA of 15.33, and a PEG ratio of 0.33, suggesting strong growth potential relative to its price. <BR><BR>In comparison to peers, Raaj Medisafe's valuation metrics stand out, particularly when contrasted with Poly Medicure, which has a PE ratio of 66.7, and Blue Jet Health at 51.29, both categorized as very expensive. The company's return on equity (ROE) is notably high at 27.28%, further reinforcing its attractive valuation. Despite recent underperformance against the Sensex, with a year-to-date return of -8.43% compared to the Sensex's 5.59%, the long-term performance over three and five years shows significant outperformance, suggesting that the current price presents a compelling buying opportunity.

What is the technical trend for Raaj Medisafe?

As of June 3, 2025, Raaj Medisafe's technical trend is mildly bearish, influenced by daily moving averages and a monthly MACD, despite some mixed signals from the weekly MACD and Bollinger Bands.

As of 3 June 2025, the technical trend for Raaj Medisafe has changed from sideways to mildly bearish. The weekly MACD is bullish, but the monthly MACD is mildly bearish, indicating mixed signals. The daily moving averages are mildly bearish, reinforcing the current trend. The Bollinger Bands show a mildly bullish stance on both weekly and monthly time frames, which contrasts with the overall bearish sentiment. The KST is bullish weekly but mildly bearish monthly, while Dow Theory indicates a mildly bearish trend on the weekly chart. Overall, the current technical stance is mildly bearish, driven primarily by the daily moving averages and the monthly MACD.

Has Raaj Medisafe declared dividend?

No Dividend History Available